Company Overview and News

0
Cassini Resources distributes tax credits to shareholders

2018-06-17 proactiveinvestors.com.au
Cassini Resources Ltd (ASX:CZI) will distribute $179,861 worth of tax credits to shareholders that were on the share register on 31 May 2018.
OZMLF OZL CSSQF CZI

48
Mining exhibits strong female board representation

2018-06-15 australianmining.com.au
The Australian Institute of Company Directors (AICD) has reported a lift in female representation across ASX200 board positions — it has climbed to 28 per cent, up from 25 per cent this time last year.
RIO BLT RIO BHPBF FSUGY RTPPF OZMLF FSUMF BHP RIO RTNTF BBL OZL BHP FMG BHPLF

0
Glencore accepts OZ Minerals’ Avanco offer, shares now stand at 73.9%

2018-06-14 australianmining.com.au
OZ Minerals this week reached acceptances in its bid for Brazilian copper-gold miner Avanco totalling 73.9 per cent of company shares.
OZMLF OZL

0
OZ Minerals nears finish line of Avanco takeover

2018-06-07 australianmining.com.au
OZ Minerals $418 million takeover bid for Brazil-focused Avanco Resources is a step closer to completion after OZ declared its unconditional.
OZMLF OZL

0
Oz Minerals boss confident in copper's future

2018-06-07 theage.com.au
The boss of Australian copper miner Oz Minerals, Andrew Cole, is confident his company’s takeover bid for the Brazilian-focused junior copper company Avanco Resources will win the backing of Avanco shareholders.
OZMLF AVB OZL

0
Oz Minerals boss confident in copper's future

2018-06-07 smh.com.au
The boss of Australian copper miner Oz Minerals, Andrew Cole, is confident his company’s takeover bid for the Brazilian-focused junior copper company Avanco Resources will win the backing of Avanco shareholders.
OZMLF AVB OZL

0
Cassini Resources begins drilling nickel-copper targets at West Musgrave

2018-06-05 proactiveinvestors.com.au
Cassini Resources Ltd (ASX:CZI) has commenced a regional exploration drilling program targeting nickel and copper targets at the West Musgrave Project in Western Australia.
OZMLF OZL CSSQF CZI

0
Copper’s growing green credentials

2018-05-30 australianmining.com.au
Emerging trends for “Green Copper” will feature in the opening session at next month’s Copper to the World Conference in Adelaide, June 26, a new addition to the program.
OZMLF OZL

0
Cassini Resources receives new data to confirm zinc target

2018-05-25 proactiveinvestors.com.au
Cassini Resources Ltd (ASX:CZI) has received new data supporting its interpretation of sedimentary zinc mineralisation at the West Arunta Project in Western Australia.
OZMLF OZL CSSQF CZI

0
Cassini Resources has "solid development project" and "significant" exploration targets

2018-05-08 proactiveinvestors.com.au
Cassini Resources Ltd (ASX:CZI) managing director Richard Bevan tells Proactive Investors that the base and precious metals explorer and developer now has, "a really solid development project with a great portfolio of exploration assets."
OZMLF OZL CSSQF CZI

0
OZ Minerals takeover bid for Avanco hits road bump

2018-05-08 australianmining.com.au
OZ Minerals’ recent $418 million takeover offer for Brazilian-focused copper-gold company Avanco Resources has been referred to by some Avanco shareholders, primarily commenters from the company’s second-biggest investor, London-based Greenstone Resources (16.68 per cent), as undervalued.
OZMLF AVB OZL

0
Drilling at Alvito IOCG Project Commences

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Avrupa Minerals Ltd. (TSXV:AVU) (OTC:AVPMF) (FRANKFURT:8AM) is pleased to present an update on the Alvito Project in South Portugal. Exploration work is funded by OZ Minerals, who are spending A$ 1 million on exploration to earn-in to 51% of the 300-square kilometer Project. To date Avrupa has completed ground magnetics and gravity geophysical surveys, geological mapping, rock chip sampling, and drill targeting.
AVU OZMLF AVPMF OZL

1
Copper to the World gets the scoop on growth trajectory

2018-05-01 australianmining.com.au
Australia’s copper sector is on the rise as global issues of energy, climate change and transportation become more urgent.
NCMGF OZMLF NCM NCMGY OZL

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:OZL / OZ MINERALS LIMITED on message board site Silicon Investor.

OZLU Water treatment